HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options.
Antiretroviral treatment
Dual infection
Guinea-Bissau
HIV-1
HIV-2
West Africa
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
04 02 2020
04 02 2020
Historique:
received:
16
06
2019
accepted:
21
01
2020
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Despite advances in the treatment quality of HIV throughout the world, several countries are still facing numerous obstacles in delivering HIV treatment at a sufficiently high quality, putting patients' lives in jeopardy. The aim of this status article is to give an overview of HIV treatment outcomes in the West African country, Guinea-Bissau, and to assess how newer treatment strategies such as long-acting injectable drugs or an HIV cure may limit or stop the HIV epidemic in this politically unstable and low-resource setting. Several HIV cohorts in Guinea-Bissau have been established and are used as platforms for epidemiological, virological, immunological and clinical studies often with a special focus on HIV-2, which is prevalent in the country. The Bandim Health Project, a demographic surveillance site, has performed epidemiological HIV surveys since 1987 among an urban population in the capital Bissau. The Police cohort, an occupational cohort of police officers, has enabled analyses of persons seroconverting with estimated times of seroconversion among HIV-1 and HIV-2-infected individuals, allowing incidence measurements while the Bissau HIV Cohort and a newer Nationwide HIV Cohort have provided clinical data on large numbers of HIV-infected patients. The HIV cohorts in Guinea-Bissau are unique platforms for research and represent real life in many African countries. Poor adherence, lack of HIV viral load measurements, inadequate laboratory facilities, high rates of loss to follow-up, mortality, treatment failure and resistance development, are just some of the challenges faced putting the goal of "90-90-90″ for Guinea-Bissau well out of reach by 2020. Maintaining undetectable viral loads on treatment as a prerequisite of a cure strategy seems not possible at the moment. Thinking beyond one-pill-once-a-day, long-acting antiretroviral treatment options such as injectable drugs or implants may be a better treatment option in settings like Guinea-Bissau and may even pave the way for an HIV cure. If the delivery of antiretroviral treatment in sub-Saharan Africa in a sustainable way for the future should be improved by focusing on existing treatment options or through focusing on new treatment options remains to be determined.
Identifiants
pubmed: 32019545
doi: 10.1186/s12981-020-0259-6
pii: 10.1186/s12981-020-0259-6
pmc: PMC6998355
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Références
J Acquir Immune Defic Syndr. 2018 Nov 1;79(3):386-393
pubmed: 30044302
APMIS. 2011 Aug;119(8):487-97
pubmed: 21749448
BMJ Open. 2013 Oct 25;3(10):e003499
pubmed: 24163204
HIV Med. 2018 Jul;19(6):403-410
pubmed: 29573304
Afr J AIDS Res. 2013 Mar;12(1):1-8
pubmed: 25871305
Retrovirology. 2010 Mar 22;7:23
pubmed: 20307309
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
AIDS. 2016 Jan 28;30(3):487-93
pubmed: 26765939
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
Trop Med Int Health. 2016 Feb;21(2):253-62
pubmed: 26616349
J Virol Methods. 2019 Jun;268:42-47
pubmed: 30871983
AIDS. 2016 Oct 23;30(16):2415-2426
pubmed: 27525551
J Int AIDS Soc. 2017 Nov;20 Suppl 7:
pubmed: 29130601
J Clin Virol. 2015 Mar;64:12-5
pubmed: 25728072
AIDS Res Hum Retroviruses. 2004 Mar;20(3):347-8
pubmed: 15117459
N Engl J Med. 2012 Jul 19;367(3):224-32
pubmed: 22808957
Int J Infect Dis. 2014 Nov;28:35-40
pubmed: 25223805
Scand J Infect Dis. 2000;32(2):169-75
pubmed: 10826903
Lancet Glob Health. 2015 Mar;3(3):e169-77
pubmed: 25701995
Bull World Health Organ. 2014 Dec 1;92(12):909-14
pubmed: 25552775
Antimicrob Agents Chemother. 2013 Jun;57(6):2751-60
pubmed: 23571535
AIDS. 2014 May 15;28(8):1161-9
pubmed: 24583671
J Virol. 2005 Jul;79(14):8979-90
pubmed: 15994792
J Int Assoc Provid AIDS Care. 2016 Jul;15(4):350-8
pubmed: 26297492
Clin Infect Dis. 2009 Jun 15;48(12):1790-3
pubmed: 19438401
J Infect Dis. 2014 Mar 1;209(5):721-8
pubmed: 23935204
J Infect Dis. 2019 May 5;219(11):1749-1754
pubmed: 30715363
PLoS One. 2011 Feb 18;6(2):e17025
pubmed: 21365013
AIDS. 2014 Feb 20;28(4):614-5
pubmed: 24469002
Lancet. 1989 Apr 15;1(8642):827-31
pubmed: 2564911
AIDS. 2006 Jun 12;20(9):1303-11
pubmed: 16816560
Int J STD AIDS. 2010 Sep;21(9):631-5
pubmed: 21097735
AIDS. 2018 Jun 1;32(9):1193-1198
pubmed: 29683842
J Antimicrob Chemother. 2017 Jul 1;72(7):2083-2088
pubmed: 28369593
J Antimicrob Chemother. 2008 Nov;62(5):914-20
pubmed: 18718922
J Virol. 2012 Jan;86(2):961-71
pubmed: 22072782
AIDS. 2016 Jun 19;30(10):1687-8
pubmed: 27243780
AIDS Res Hum Retroviruses. 2015 Sep;31(9):938-45
pubmed: 26066756
Lancet Infect Dis. 2010 Mar;10(3):155-66
pubmed: 20185094
Science. 1986 Jul 18;233(4761):343-6
pubmed: 2425430
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):e100-8
pubmed: 25886921
Virol J. 2015 Mar 11;12:41
pubmed: 25889017
AIDS. 2014 Apr 24;28(7):949-57
pubmed: 24812673
Retrovirology. 2015 Feb 05;12:10
pubmed: 25808007
J Clin Microbiol. 2009 Jul;47(7):2200-8
pubmed: 19420165
J Antimicrob Chemother. 2011 Jul;66(7):1484-8
pubmed: 21558334
AIDS Res Hum Retroviruses. 2013 Mar;29(3):470-8
pubmed: 23088167
J Int AIDS Soc. 2015 Sep 29;18:20243
pubmed: 26426197
Int J Infect Dis. 2015 Mar;32:128-34
pubmed: 25499041
Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8
pubmed: 18227188
AIDS. 2008 Jun 19;22(10):1195-202
pubmed: 18525265
AIDS. 1999;13 Suppl A:S69-84
pubmed: 10885765
J Infect Dev Ctries. 2010 Jun 03;4(5):301-8
pubmed: 20539062
Lancet HIV. 2019 Apr;6(4):e214-e215
pubmed: 30942185
AIDS. 1998 Sep 10;12(13):1707-14
pubmed: 9764792
Int J Epidemiol. 2015 Jun;44(3):756-63
pubmed: 25342251
PLoS One. 2018 Oct 31;13(10):e0206406
pubmed: 30379960
Sex Transm Infect. 2007 Oct;83(6):463-7
pubmed: 17611233
AIDS. 2016 Jul 17;30(11):1713-22
pubmed: 27163705
AIDS. 2007 May 31;21(9):1185-97
pubmed: 17502729
AIDS. 2009 Jul 31;23(12):1575-82
pubmed: 19521234
J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):87-90
pubmed: 23982658
J Antimicrob Chemother. 2019 Feb 1;74(2):462-467
pubmed: 30418575
J Acquir Immune Defic Syndr. 2019 Apr 15;80(5):542-550
pubmed: 30865050
mBio. 2019 Jan 8;10(1):
pubmed: 30622192
Acta Trop. 2019 Apr;192:144-150
pubmed: 30771284
Infection. 2017 Apr;45(2):187-197
pubmed: 27743308
Clin Infect Dis. 2015 Oct 15;61(8):1346-7
pubmed: 26187019
Retrovirology. 2010 May 19;7:46
pubmed: 20482865
Curr Opin HIV AIDS. 2016 Sep;11(5):537-544
pubmed: 27254747
AIDS. 2010 Nov 13;24(17):2753-5
pubmed: 20827161
Pan Afr Med J. 2016 Sep 29;25:40
pubmed: 28154729
AIDS. 2008 Oct 1;22(15):1897-908
pubmed: 18784453
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736
Retrovirology. 2010 Jun 04;7:50
pubmed: 20525366
Antivir Ther. 2004 Feb;9(1):57-65
pubmed: 15040537
J Acquir Immune Defic Syndr. 1993 Aug;6(8):941-8
pubmed: 8315578
J Infect Dis. 2010 Apr 15;201(8):1150-4
pubmed: 20199244
AIDS. 2017 Jan 28;31(3):427-436
pubmed: 27831953
PLoS One. 2014 Jun 10;9(6):e99971
pubmed: 24915064
Lancet HIV. 2018 Nov 1;:null
pubmed: 30392769
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Aug 1;9(4):422-8
pubmed: 7600111